Orthofix Medical stock analysis
Want to see OFIX full AI Analyst Report?
Orthofix Medical (OFIX) Stock Price & Analysis
OFIX Stock Chart & Stats
- Day’s Range
- $7.09 - $7.32
- 52-Week Range
- $6.52 - $16.42
- Previous Close
- $6.94
- Volume
- N/A
- Average Volume (3M)
- 584.14K
- Market Cap
- $292.25M
- Enterprise Value
- $562.65M
- Total Cash (Recent Filing)
- $86.32M
- Total Debt (Recent Filing)
- $234.85M
- Price to Earnings (P/E)
- ―
- Beta
- 0.89
- Next Earnings
- Feb 19, 2027 (Est.)
- EPS Estimate
- -0.07
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Margin Improvement
Strong revenue growth alongside higher EBITDA margins indicates improving operating leverage and better execution. Although profitability is not complete, the combination of scale and cost discipline can strengthen earnings capacity and provide a more durable foundation for future investment.
Limb Reconstruction Adoption
Growth in Limb Reconstruction is supported by continued adoption of named products and strong international demand, rather than only broad market expansion. This creates a durable growth channel that can diversify Orthofix beyond weaker spinal markets over coming quarters.
Commercial Partner Productivity
Concentrating resources behind stronger distributors and improving asset turns can make the commercial model more productive and focused. Over time, this approach may improve account execution, reduce inefficient relationships, and support better returns from the spinal portfolio.
Bears Say
Persistent Cash Burn
Deeply negative free cash flow means the business is not currently self-funding despite improving revenue and EBITDA. Continued investment or working-capital needs may require external financing or constrain strategic flexibility until cash conversion improves consistently.
Incomplete Profitability And Rising Leverage
Ongoing net losses limit the benefit of gross-margin and EBITDA progress, while higher leverage reduces flexibility relative to prior periods. Together, these factors can constrain investment capacity and leave less room to absorb operating setbacks over the next several quarters.
Spine Execution And MDR Headwinds
Weak U.S. Spine performance and execution constraints threaten an important product area, while MDR requirements create a defined regulatory revenue reduction. The combined pressure may delay portfolio growth and require sustained investment before the business regains momentum.
OFIX FAQ
What was Orthofix Medical’s price range in the past 12 months?
What is Orthofix Medical’s market cap?
When is Orthofix Medical’s upcoming earnings report date?
How were Orthofix Medical’s earnings last quarter?
Is Orthofix Medical overvalued?
Does Orthofix Medical pay dividends?
What is Orthofix Medical’s EPS estimate?
How many shares outstanding does Orthofix Medical have?
What happened to Orthofix Medical’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Orthofix Medical?
What is the TipRanks Smart Score and how is it calculated?
Orthofix Medical Stock Smart Score
Company Description
Orthofix Medical
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Massimo Calafiore
- Employees
- 1,605
- Website
- www.orthofix.com
- Address
- 3451 Plano Parkway, Lewisville, TX, 75056, US
Orthofix Medical (OFIX) Earnings & Revenues
OFIX Company Deck
OFIX Earnings Call
Earnings Call SentimentNeutral
The call presented a mixed outlook. Limb Reconstruction, Therapeutic Solutions, Biologics stabilization, technology launches and improved adjusted EBITDA were positive, but these were offset by below-expectation results, U.S. Spine weakness, supplier and instrument constraints, reduced 2026 guidance, unfavorable mix, cash timing pressure and a stated 2027 MDR revenue headwind.
View all OFIX earnings summariesOFIX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |









